Anti-coagulant aptamers

被引：43

作者：

Gopinath, Subash Chandra Bose ^{[1
,2
]}

机构：

[1] Natl Inst Adv Ind Sci & Technol, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058562, Japan

[2] Natl Inst Adv Ind Sci & Technol, CAN FOR, Tsukuba, Ibaraki 3058562, Japan

来源：

THROMBOSIS RESEARCH | 2008年 / 122卷 / 06期

关键词：

D O I：

10.1016/j.thromres.2007.10.022

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the past decade development of aptamer technology is poised into several fields with various clinical applications. With this progress, aptamer based anti-coagulant agents are evolved and continuing their applications with clinical trials. At present several anti-coagulant aptamers are available against different proteins from blood coagulation cascade. In this review, the mechanism and functions of anti-coagulant aptamers, as an alternate candidate to other available anti-coagulant agents are discussed. (C) 2007 Elsevier Ltd. All rights reserved.

引用

收藏

页码：838 / 847

页数：10

相关论文

共 42 条

[1]

Adler Brian K, 2004, Clin Lab Sci, V17, P113

[2] Designing highly specific biosensing surfaces using aptamer monolayers on gold [J].

Balamurugan, Subramanian ;

Obubuafo, Anne ;

Soper, Steven A. ;

McCarley, Robin L. ;

Spivak, David A. .

LANGMUIR, 2006, 22 (14) :6446-6453

[3] Nucleic acid aptamers in therapeutic anticoagulation - Technology, development and clinical application [J].

Becker, RC ;

Rusconi, C ;

Sullenger, B .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (06) :1014-1020

[4] SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN [J].

BOCK, LC ;

GRIFFIN, LC ;

LATHAM, JA ;

VERMAAS, EH ;

TOOLE, JJ .

NATURE, 1992, 355 (6360) :564-566

[5]

Chen SWW, 2002, THROMB HAEMOSTASIS, V88, P74

[6] Aptamer:toxin conjugates that specifically target prostate tumor cells [J].

Chu, Ted C. ;

Marks, John W., III ;

Lavery, Laura A. ;

Faulkner, Sarah ;

Rosenblum, Michael G. ;

Ellington, Andrew D. ;

Levy, Matthew .

CANCER RESEARCH, 2006, 66 (12) :5989-5992

[7] First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity [J].

Dyke, Christopher K. ;

Steinhubl, Steven R. ;

Kleiman, Neal S. ;

Cannon, Richard O. ;

Aberle, Laura G. ;

Lin, Min ;

Myles, Shelley K. ;

Melloni, Chiara ;

Harrington, Robert A. ;

Alexander, John H. ;

Becker, Richard C. ;

Rusconi, Christopher P. .

CIRCULATION, 2006, 114 (23) :2490-2497

[8] Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function [J].

Gal, SW ;

Amontov, S ;

Urvil, PT ;

Vishnuvardhan, D ;

Nishikawa, F ;

Kumar, PKR ;

Nishikawa, S .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 252 (03) :553-562

[9] Snake-venom-derived factor IX-binding protein specifically blocks the γ-carboxyglutamic acid-rich-domain-mediated membrane binding of human factors IX and X [J].

Gopinath, Subash C. B. ;

Shikamoto, Yasuo ;

Mizuno, Hiroshi ;

Kumar, Pennnetcha K. R. .

BIOCHEMICAL JOURNAL, 2007, 405 (351-357) :351-357

[10] A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway [J].

Gopinath, Subash C. B. ;

Shikamoto, Yasuo ;

Mizuno, Hiroshi ;

Kumar, Penmetcha K. R. .

THROMBOSIS AND HAEMOSTASIS, 2006, 95 (05) :767-771

← 1 2 3 4 5 →